打开APP

Halozyme 医疗公司与辉瑞达成生物制剂协议

  1. Halozyme
  2. 辉瑞

来源:生物谷 2012-12-23 20:57

2012年12月23日讯 /生物谷BIOON/ --Halozyme医疗公司与辉瑞达成一项生物制剂协议,该协议使Halozyme公司能够更好地利用其重组人类透明质酸酶(rHuPH20)技术来改进蛋白质疗法。根据这项技术的潜在价值,辉瑞公司将为协议支付高达八百万美元。如果该研究达到预期目标后,Halozyme可能获得的潜在收入将超过5亿美元。

2012年12月23日讯 /生物谷BIOON/ --Halozyme医疗公司与辉瑞达成一项生物制剂协议,该协议使Halozyme公司能够更好地利用其重组人类透明质酸酶(rHuPH20)技术来改进蛋白质疗法。根据这项技术的潜在价值,辉瑞公司将为协议支付高达八百万美元。如果该研究达到预期目标后,Halozyme可能获得的潜在收入将超过5亿美元。

消息公布后,Halozyme的股票价格上涨了17.75%,达到每股6.55美元。(生物谷Bioon.com)

详细英文报道:

Near the close of what has been a rocky year, Halozyme Therapeutics ($HALO) has picked up a deal with the biologics folks at Pfizer ($PFE). The pact gives the San Diego-based biotech another major pharma collaborator to advance its recombinant human hyaluronidase enzyme (rHuPH20) technology for improving the delivery of protein therapies.

Like most such deals, this one promises the bulk of its potential payments down the road. Pfizer is paying up $8 million for licenses to Halozyme's drug technology for two treatment targets in primary and specialty care on an exclusive basis with the right to snag four more targets if the drug giant ponies up more money. Add up all the potential payments, not including royalties, and Halozyme stands to gobble up $507 million more if all goes as hoped.

San Diego-based Halozyme's stock price jumped 17.75% to $6.55 this morning in pre-market trading.

Halozyme's shares took a beating earlier this year after U.S. regulators raised concerns about antibodies against rHuPH20 in patients who took an immune deficiency treatment from partner Baxter that uses the enzyme ingredient. Halozyme relies heavily on partners such as Baxter, ViroPharma and Roche ($RHHBY) to carry its technology toward the market.

The Pfizer deal shows that biologics experts have faith in Halozyme's platform to improve the properties of their drugs, and investors appear to be responding positively.

"I am delighted about this opportunity as it has the potential to enhance Pfizer's ability to optimize treatments for patients," Jose Carlos Gutierrez-Ramos, head of Pfizer BioTherapeutics R&D, said in a statement.

 

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->